Breaking News Instant updates and real-time market news.

CORI

Corium

$10.16

0.25 (2.52%)

, NEOS

Neos Therapeutics

$8.70

-0.5 (-5.43%)

09:33
09/19/17
09/19
09:33
09/19/17
09:33

Mizuho to hold a conference

Biotechnology CNS Deep Management Day is being held in Boston on September 19.

CORI

Corium

$10.16

0.25 (2.52%)

NEOS

Neos Therapeutics

$8.70

-0.5 (-5.43%)

VYGR

Voyager Therapeutics

$17.36

1.01 (6.18%)

  • 25

    Sep

CORI Corium
$10.16

0.25 (2.52%)

12/16/16
CANT
12/16/16
INITIATION
Target $10
CANT
Overweight
Corium initiated with an Overweight at Cantor
Cantor Fitzgerald analyst William Tanner started Corium with an Overweight rating and $10 price target.
12/22/16
NEED
12/22/16
NO CHANGE
NEED
AMAG Pharmaceuticals, Corium top pharma picks for 2017 at Needham
Needham analyst Serge Belanger says that while 2016 kicked off with "the wrong kind of bang" for specialty pharma/biopharma equities, with the unraveling of the rollup strategies espoused by Valeant Pharmaceuticals (VRX) and Endo (ENDP) and the political rhetoric around drug pricing as headwinds throughout the year, the election outcome provides a more positive outlook for 2017. Nonetheless, the analyst believes the political uncertainty around drug pricing is likely to remain an ongoing but diminished concern with the new administration. Additionally, he expects some of the proposed tax changes of the new administration to be key drivers for driving M&A volumes in 2017 and beyond. Belanger believes this bodes well for companies in the classic spec pharma therapeutics areas that have historically benefited from consolidation, and said his top picks for 2017 are AMAG Pharmaceuticals (AMAG) and Corium (CORI).
01/04/17
LEER
01/04/17
NO CHANGE
Target $14
LEER
Outperform
Leerink lowers Corium target on lower probability of success for Twirla
Leerink analyst Jason Gerberry says Agile Therapeutics (AGRX) announced Phase 3 top-line data for Twirla, a levonorgestrel and ethinyl estradiol transdermal patch contraceptive. Noting that Corium (CORI) is Agile's manufacturer partner, the analyst lowered his price target on the former's shares to $14 from $16 and reduced his peak sales projection and probability of success for Twirla to 35% from 75%. He reiterates an Outperform rating on Corium's stock.
NEOS Neos Therapeutics
$8.70

-0.5 (-5.43%)

07/31/17
CANT
07/31/17
INITIATION
Target $20
CANT
Overweight
Neos Therapeutics initiated with an Overweight at Cantor
Cantor Fitzgerald analyst Louise Chen started Neos Therapeutics with an Overweight rating and $20 price target. The analyst thinks the sales potential of the company's attention-deficit/hyperactivity disorder platform is underappreciated at current share levels.
08/01/17
08/01/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Hain Celestial (HAIN) initiated with a Hold at Loop Capital. 2. Centennial Resource Development (CDEV) initiated with an Overweight at JPMorgan. 3. Neos Therapeutics (NEOS) initiated with an Overweight at Cantor. 4. Celldex (CLDX) assumed with a Buy at H.C. Wainwright. 5. SilverBow Resorces (SBOW) initiated with a Neutral at Seaport Global. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/15/17
BMOC
09/15/17
NO CHANGE
BMOC
Neos' Adzens ER approval 'rounds out ADHD portfolio,' says BMO Capital
BMO Capital analyst Gary Nachman said that while the FDA approval of Adzenys ER which was announced after the close was expected, it was good to see it get "over the goal line," as he believes it will "round out" Neos Therapeutics' ADHD portfolio. Nachman reiterated his Outperform rating and $14 price target on Neos shares.
09/18/17
JMPS
09/18/17
NO CHANGE
Target $30
JMPS
Outperform
JMP says Neos has most complete offering of alternative dose ADHD drugs
JMP Securities analyst Jason Butler said Neos Therapeutics' approval of Adzenys ER Oral Solution further builds out the company's ADHD portfolio, giving it the most complete offering of alternative dose forms of the most widely prescribed drugs used to treat the condition. He keeps an Outperform rating and $30 price target on Neos shares.
VYGR Voyager Therapeutics
$17.36

1.01 (6.18%)

03/01/17
NOMU
03/01/17
INITIATION
Target $31
NOMU
Buy
Voyager Therapeutics initiated with a Buy at Nomura
Nomura initiated Voyager Therapeutics with a Buy and a $31 price target.
03/31/17
STFL
03/31/17
NO CHANGE
STFL
Voyager Therapeutics has reached attractive entry point, says Stifel
After meeting with Voyager's CEO, Stifel analyst Katherine Breedis says that the company "continues to make solid progress" with its top drug, VY-AADC01. The analyst notes that the company is slated to report Phase 1B six month data for the drug in the middle of this year, and she says that it could be an important positive turning point for the shares. The analyst adds that the data may have been "de-risked" by recent improved outcomes reported by the company. Breedis thinks that VY-AADC01 has several key potential positive catalysts over the next 6-9 months,. She thinks that the stock has reached an attractive entry point and keeps a $33 price target and a Buy rating on the stock.
07/28/17
STFL
07/28/17
INITIATION
STFL
Buy
Voyager Therapeutics coverage resumed with a Buy at Stifel
Stifel analyst Thmas Shrader resumed coverage of Voyager with a $20 price target and a Buy rating. He thinks that the company's lead drug, a treatment for Parkinson's "has great promise."
08/16/17
EVER
08/16/17
INITIATION
Target $21
EVER
Outperform
Voyager Therapeutics initiated with an Outperform at Evercore ISI
Evercore ISI analyst Josh Schimmer initiated Voyager Therapeutics with an Outperform and a $21 price target.

TODAY'S FREE FLY STORIES

IPXL

Impax

$19.95

-0.85 (-4.09%)

17:55
10/16/17
10/16
17:55
10/16/17
17:55
Hot Stocks
Impax jumps 6% in after-hours after WSJ says Amneal deal near »

Shares of Impax are up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Nov

IPXL

Impax

$19.95

-0.85 (-4.09%)

17:51
10/16/17
10/16
17:51
10/16/17
17:51
Periodicals
Impax and Amneal close to merger pact, WSJ says »

Impax Laboratories and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Nov

AGII

Argo Group

$62.90

-0.25 (-0.40%)

17:36
10/16/17
10/16
17:36
10/16/17
17:36
Hot Stocks
Argo Group provides preliminary Q3 loss estimate »

Argo Group announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FDEF

First Defiance Financial

$53.65

-0.25 (-0.46%)

17:34
10/16/17
10/16
17:34
10/16/17
17:34
Earnings
First Defiance Financial reports Q3 EPS 92c, consensus 89c »

Reports Q3 NII $ $25.0M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

BRO

Brown & Brown

$48.97

-0.42 (-0.85%)

17:33
10/16/17
10/16
17:33
10/16/17
17:33
Earnings
Brown & Brown reports Q3 EPS 53c, consensus 50c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

ORIG

Ocean Rig UDW

$26.18

0.51 (1.99%)

17:31
10/16/17
10/16
17:31
10/16/17
17:31
Hot Stocks
Ocean Rig holder BlueMountain intends to recommend company hire advisers »

Ocean Rig UDW holder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$202.68

3.19 (1.60%)

, IMDZ

Immune Design

$10.10

-0.85 (-7.76%)

17:31
10/16/17
10/16
17:31
10/16/17
17:31
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS:…

NFLX

Netflix

$202.68

3.19 (1.60%)

IMDZ

Immune Design

$10.10

-0.85 (-7.76%)

SAVE

Spirit Airlines

$33.47

-0.33 (-0.98%)

UNH

UnitedHealth

$193.20

0.68 (0.35%)

BMI

Badger Meter

$50.80

-0.6 (-1.17%)

SONC

Sonic

$24.80

0.42 (1.72%)

ABEO

Abeona Therapeutics

$16.70

0.6 (3.73%)

VICL

Vical

$2.86

0.04 (1.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 16

    Oct

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 22

    Oct

  • 23

    Oct

  • 08

    Nov

  • 17

    Oct

FDC

First Data

$18.01

0.39 (2.21%)

17:28
10/16/17
10/16
17:28
10/16/17
17:28
Hot Stocks
First Data CAO sells 3,996 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 30

    Oct

ROSG

Rosetta Genomics

$1.00

-0.0479 (-4.57%)

17:28
10/16/17
10/16
17:28
10/16/17
17:28
Syndicate
Breaking Syndicate news story on Rosetta Genomics »

Rosetta Genomics files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HRS

Harris

$135.90

-0.66 (-0.48%)

17:27
10/16/17
10/16
17:27
10/16/17
17:27
Hot Stocks
Harris awarded $100M government contract modification »

Harris Corp., Clifton,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$259.75

-0.99 (-0.38%)

17:26
10/16/17
10/16
17:26
10/16/17
17:26
Hot Stocks
Boeing awarded $240.2M government contract »

The Boeing Co., Oklahoma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

PI

Impinj

$34.98

-0.71 (-1.99%)

17:22
10/16/17
10/16
17:22
10/16/17
17:22
Hot Stocks
Impinj COO sells 7,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

  • 14

    Nov

  • 15

    Nov

ADOM

Adomani

$6.50

-0.36 (-5.25%)

17:21
10/16/17
10/16
17:21
10/16/17
17:21
Syndicate
Breaking Syndicate news story on Adomani »

Adomani files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAVE

Spirit Airlines

$33.47

-0.33 (-0.98%)

17:20
10/16/17
10/16
17:20
10/16/17
17:20
Hot Stocks
Spirit Airlines raises Q3 total RASM view to (6.5%) from (8.5%)-(7%) »

Sees Q3 ASMs up 18%. Sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RESN

Resonant

$4.38

-0.08 (-1.79%)

17:16
10/16/17
10/16
17:16
10/16/17
17:16
Hot Stocks
Breaking Hot Stocks news story on Resonant »

Longboard raises stake in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CZR

Caesars

$11.85

-0.3 (-2.47%)

17:14
10/16/17
10/16
17:14
10/16/17
17:14
Hot Stocks
Breaking Hot Stocks news story on Caesars »

TPG Group reports 14.3%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

IPSEY

Ipsen

$35.23

1.2 (3.53%)

, EXEL

Exelixis

$29.02

4.26 (17.21%)

17:08
10/16/17
10/16
17:08
10/16/17
17:08
Hot Stocks
Ipsen says Phase 3 Celestial trial of cabozanitinib met primary endpoint of OS »

Before the market opened,…

IPSEY

Ipsen

$35.23

1.2 (3.53%)

EXEL

Exelixis

$29.02

4.26 (17.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 06

    Nov

GOGL

Golden Ocean

$8.50

0.02 (0.24%)

17:06
10/16/17
10/16
17:06
10/16/17
17:06
Syndicate
Golden Ocean files to sell $66M of common stock »

DNB Markets, Arctic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSQ

Townsquare Media

$10.42

0.27 (2.66%)

17:03
10/16/17
10/16
17:03
10/16/17
17:03
Hot Stocks
Townsquare Media appoints Bill Wilson and Dhruv Prasad as co-CEOs »

Townsquare Media has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WPX

WPX Energy

$10.90

0.16 (1.49%)

17:03
10/16/17
10/16
17:03
10/16/17
17:03
Initiation
WPX Energy initiated  »

WPX Energy initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Nov

TRQ

Turquoise Hill

$3.36

0.02 (0.60%)

17:02
10/16/17
10/16
17:02
10/16/17
17:02
Hot Stocks
Turquoise Hill sees FY17 Oyu Tolgoi copper production 130K-160K tonnes »

Oyu Tolgoi is expected to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EGN

Energen

$53.18

0.3 (0.57%)

17:02
10/16/17
10/16
17:02
10/16/17
17:02
Initiation
Energen initiated  »

Energen initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRQ

Turquoise Hill

$3.36

0.02 (0.60%)

17:02
10/16/17
10/16
17:02
10/16/17
17:02
Hot Stocks
Turquoise Hill reports Q3 Oyu Tolgoi material mined up 9% y/y »

In 3Q17, material mined…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AHL

Aspen Insurance

$41.40

-0.35 (-0.84%)

17:00
10/16/17
10/16
17:00
10/16/17
17:00
Hot Stocks
Aspen Insurance reports preliminary pre-tax hurricane impact of $310M »

Aspen Insurance reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

JAG

Jagged Peak Energy

$13.95

0.03 (0.22%)

17:00
10/16/17
10/16
17:00
10/16/17
17:00
Initiation
Jagged Peak Energy initiated  »

Jagged Peak Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.